Next Generation Theranostics

circles design

TetraKit: Next Generation Theranostics

Targeted radionuclide therapy is an emerging field that has shown great promise in the treatment of late-stage metastatic cancer. Theranostics combines radionuclide therapy with diagnosis by nuclear imaging. In theranostics, cancer-targeting molecules, known as radiopharmaceuticals, carry radioactive atoms specifically to tumors. Depending on which type of radiation is chosen, physicians can either diagnose the severity and spread of the cancer or treat it by selectively destroying the cancerous tissue. TetraKit is a new, click chemistry based radiochemical platform, which allows for labeling of virtually any cancer-targeting molecule with any radionuclide pair for theranostics. TetraKit Technologies focuses its development program on fluorine-18 and astatine-211 as this pair is the best suited radionuclide pair for PET imaging and targeted alpha-radionuclide therapy. Alpha-therapy has attracted wide interest in current oncology as it succeeded where conventional therapies failed. TetraKit will develop the next generation of theranostic radiopharmaceuticals, which will improve patient care and disease outcomes.

Logo transparent

Latest news

from TetraKit Technologies

March 18, 2024

7th Theranostics World Congress

We are thrilled to announce our participation in the upcoming 7th Theranostics World Congress, where our esteemed experts will be sharing groundbreaking insights and innovations in the field of theranostics.

Dr. Andreas Jensen, CEO and co-founder of TetraKit Technologies, will be giving a talk on March 24th, highlighting our platform’s inventive application in next-generation theranostics.

Dr. Matthias Herth, our CSO, will take the stage on March 23rd to discuss ²¹¹At-PSMA for alpha-RLT (Radioligand Therapy) of prostate cancer, showcasing TetraKit’s advancements in personalized cancer treatment.

Dr. Marcel Martin, our Senior Radiochemistry expert, will present on March 24th, focusing on new dimeric FAPi radioligands and their optimized properties for radioligand therapy to improve therapeutic efficacy.

Join us at our booth during the conference for engaging discussions, valuable insights, and a closer look at our latest innovations. Your presence will add immense value to these special occasions as we collectively explore the future of theranostics and healthcare innovation.

Don’t miss this opportunity to connect, learn, and collaborate! Visit the 7th Theranostics World Congress website and join our presentations. See you there! 🚀 #TetraKitTechnologies #TheranosticsWorldCongress #HealthcareInnovation

Read more

October 11, 2023


The 4th Working Group and Core Group meeting of the COST Action CA19114 / COST NOAR Astatine – Network for Optimized Astatine-labeled Radiopharmaceuticals is currently underway. The meeting is being held at the Faculty of Pharmacy, University of Ljubljana in Slovenia, from October 9th to 11th, 2023. Stay tuned for updates on the latest developments in the field of optimized astatine-labeled radiopharmaceuticals.

Read more

September 12, 2023

Highlight lecture

Today at #EANM23 in Vienna, Dr. Umberto Battisti presented our data and findings as an EANM-highlighted lecture. We are grateful for the opportunity to show our data to the scientific community dedicated to this field.
Please reach out if you want to hear more about our platform technology.
#Radiotheranostics #TetraKitTechnologies

Read more

Message from the CEO

Andreas Jensen, PhD

Andreas Jensen, PhD

Chief Executive Officer

Message from the CEO

“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”

Message from the CSO

Matthias Herth, PhD

Matthias Herth, PhD

Chief Scientific Officer

Message from the CSO

“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”